세계의 근이완제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약물 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Muscle Relaxant Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2020-2030F
근이완제 세계 시장 규모는 2024년 38억 5,000만 달러에 달했고, 2030년까지 예측 기간 동안 연평균 4.40%의 안정적인 성장을 보일 것으로 예상됩니다.
근이완제 세계 시장은 근육 경련, 경직 및 비자발적 수축을 완화하기 위해 고안된 의약품의 연구, 개발, 생산, 유통 및 상품화를 포괄하는 제약 산업의 중요한 부문을 구성하고 있습니다. 이 약물들은 신경 경로를 표적으로 삼아 중추신경계(CNS)에 직접 작용하거나 말초신경의 활동을 조절하여 근육 이완을 촉진합니다. 근육 긴장, 염좌, 만성 요통, 섬유근육통, 다발성 경화증, 신경 질환에 따른 경련 치료에 널리 처방되고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
38억 5,000만 달러 |
| 시장 규모 : 2030년 |
50억 달러 |
| CAGR : 2025-2030년 |
4.40% |
| 급성장 부문 |
경구 |
| 최대 시장 |
북미 |
근골격계 질환의 유병률 증가, 세계 인구의 고령화, 의약품 제제의 발전이 시장 확대에 박차를 가하고 있습니다. 만성 통증 및 운동 관련 질환 증가로 인해 효과적이고 내약성이 좋은 근이완제에 대한 수요가 증가하고 있습니다. 또한, 인구 통계학적 추세, 특히 고령자 비율 증가는 시장 성장을 더욱 촉진하고 있습니다. 노인들은 관절염, 골다공증, 요통에 걸리기 쉬우며, 이 모든 것이 근이완제 요법을 필요로 하기 때문입니다.
주요 시장 성장 촉진요인
근골격계 질환의 유병률 상승
주요 시장 이슈
제네릭 의약품과의 경쟁
주요 시장 동향
생물학적 제제와 새로운 치료법
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 근이완제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 약제 유형별(골격근이완제, 안면근이완제, 신경근 차단제)
- 투여 경로별(경구, 주사, 기타)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 근이완제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 근이완제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 근이완제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 근이완제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 근이완제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 근이완제 시장 : SWOT 분석
제14장 경쟁 구도
- Amneal Pharmaceuticals LLC
- Ipsen Biopharmaceuticals Inc
- Merz Pharmaceuticals LLC
- Par Pharmaceutical Inc
- Endo Pharmaceuticals Inc
- Vertical Pharmaceuticals Inc
- Mallinckrodt LLC
- Sterix Ltd
- Eisai Co Ltd
- Teva Pharmaceuticals USA Inc.
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
Global Muscle Relaxant Drugs Market was valued at USD 3.85 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.40% through 2030. The Global Muscle Relaxant Drugs Market constitutes a vital segment of the pharmaceutical industry, encompassing the research, development, production, distribution, and commercialization of medications designed to relieve muscle spasms, stiffness, and involuntary contractions. These drugs operate by targeting neurological pathways, either directly affecting the central nervous system (CNS) or modulating peripheral nerve activity, thereby promoting muscle relaxation. They are extensively prescribed for treating muscle strains, sprains, chronic back pain, fibromyalgia, multiple sclerosis, and spasticity associated with neurological conditions.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 3.85 Billion |
| Market Size 2030 | USD 5.00 Billion |
| CAGR 2025-2030 | 4.40% |
| Fastest Growing Segment | Oral |
| Largest Market | North America |
The market is undergoing rapid expansion, primarily fueled by the rising incidence of musculoskeletal disorders, an aging global population, and advancements in pharmaceutical formulations. The increasing prevalence of chronic pain and mobility-related conditions has intensified the demand for effective, well-tolerated muscle relaxants. Additionally, demographic trends particularly the growing proportion of elderly individuals have further propelled market growth, as older adults are more susceptible to arthritis, osteoporosis, and lower back pain, all of which necessitate muscle relaxant therapy.
Key Market Drivers
Rising Prevalence of Musculoskeletal Disorders
The increasing prevalence of musculoskeletal disorders (MSDs) is a major driving force behind the expansion of the Global Muscle Relaxant Drugs Market. MSDs encompass a wide range of conditions affecting the bones, muscles, ligaments, tendons, and joints, leading to chronic pain, reduced mobility, and functional impairments. The incidence of MSDs has risen sharply due to aging populations, sedentary lifestyles, workplace injuries, and increasing rates of obesity. According to the World Health Organization (WHO), an estimated 1.71 billion people worldwide are affected by musculoskeletal disorders, including lower back pain, neck pain, osteoarthritis, and rheumatoid arthritis. These conditions represent a significant global burden, driving the demand for effective treatment solutions within the pharmaceutical and healthcare industries, making them the leading cause of disability. Chronic conditions such as arthritis, lower back pain, and fibromyalgia have significantly increased the need for muscle relaxants to manage pain and improve quality of life.
Key Market Challenges
Competition from Generic Drugs
As patents for certain muscle relaxant drugs expire, the market faces increased competition from generic drug manufacturers. This competition can lead to price erosion and reduced profit margins for original drug developers. Pharmaceutical companies must navigate this challenge by differentiating their products through innovation, improved formulations, and enhanced therapeutic outcomes.
Key Market Trends
Biologics and Novel Therapies
The emergence of biologics and novel therapies is reshaping the treatment landscape. Biologics, which are derived from living organisms, offer the potential for targeted interventions with fewer side effects. As research into biologics and advanced therapies progresses, new avenues for addressing musculoskeletal disorders may emerge, providing patients with innovative treatment options.
Key Market Players
Amneal Pharmaceuticals LLC
Ipsen Biopharmaceuticals Inc
Merz Pharmaceuticals LLC
Par Pharmaceutical Inc
Endo Pharmaceuticals Inc
Vertical Pharmaceuticals Inc
Mallinckrodt LLC
Sterix Ltd
Eisai Co Ltd
Teva Pharmaceuticals USA Inc
Report Scope:
In this report, the Global Muscle Relaxant Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Muscle Relaxant Drugs Market, By Drug Type:
- Skeletal Muscle Relaxant Drugs
- Facial Muscle Relaxant Drugs
- Neuromuscular Blocking Agents
Muscle Relaxant Drugs Market, By Route of Administration:
Muscle Relaxant Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Muscle Relaxant Drugs Market, By region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Muscle Relaxant Drugs Market.
Available Customizations:
Global Muscle Relaxant Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Muscle Relaxant Drugs Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs, Neuromuscular Blocking Agents)
- 5.2.2. By Route of Administration (Oral, Injectable, Others)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Muscle Relaxant Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Muscle Relaxant Drugs Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Type
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Muscle Relaxant Drugs Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Type
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Muscle Relaxant Drugs Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Type
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By Distribution Channel
7. Europe Muscle Relaxant Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Muscle Relaxant Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Type
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By Distribution Channel
- 7.3.2. United Kingdom Muscle Relaxant Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Type
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By Distribution Channel
- 7.3.3. Italy Muscle Relaxant Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Type
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By Distribution Channel
- 7.3.4. France Muscle Relaxant Drugs Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Type
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Muscle Relaxant Drugs Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Type
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Muscle Relaxant Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Muscle Relaxant Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Type
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Muscle Relaxant Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Type
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Muscle Relaxant Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Type
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Muscle Relaxant Drugs Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Type
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Muscle Relaxant Drugs Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Type
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By Distribution Channel
9. South America Muscle Relaxant Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Muscle Relaxant Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Type
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Muscle Relaxant Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Type
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Muscle Relaxant Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Type
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Muscle Relaxant Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Muscle Relaxant Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Type
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Muscle Relaxant Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Type
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Muscle Relaxant Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Type
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Muscle Relaxant Drugs Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Amneal Pharmaceuticals LLC
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. Ipsen Biopharmaceuticals Inc
- 14.3. Merz Pharmaceuticals LLC
- 14.4. Par Pharmaceutical Inc
- 14.5. Endo Pharmaceuticals Inc
- 14.6. Vertical Pharmaceuticals Inc
- 14.7. Mallinckrodt LLC
- 14.8. Sterix Ltd
- 14.9. Eisai Co Ltd
- 14.10.Teva Pharmaceuticals USA Inc.
15. Strategic Recommendations
16. About Us & Disclaimer
